Correlation Engine 2.0
Clear Search sequence regions


  • apoptosis (3)
  • fk506 (7)
  • groups controls (2)
  • LC3 (8)
  • mice (1)
  • mrna (2)
  • protein levels (1)
  • puromycin (13)
  • tacrolimus (6)
  • Sizes of these terms reflect their relevance to your search.

    To investigate the mechanism through which tacrolimus, often used to treat refractory nephropathy, protects against puromycin-induced podocyte injury. An in vitro model of puromycin-induced podocyte injury was established by dividing podocytes into three groups: controls, puromycin only (PAN group), and puromycin plus tacrolimus (FK506 group). Podocyte morphology, number, apoptosis rate and microtubule associated protein 1 light chain 3 alpha (LC3) expression were compared. Puromycin caused podocyte cell body shrinkage and loose intercellular connections, but podocyte morphology in the FK506 group was similar to controls. The apoptosis rate was lower in the FK506 group versus PAN group. The low level of LC3 mRNA observed in untreated podocytes was decreased by puromycin treatment; however, levels of LC3 mRNA were higher in the FK506 group versus PAN group. Although LC3-I and LC3-II protein levels were decreased by puromycin, levels in the FK506 group were higher than the PAN group. Fewer podocyte autophagosomes were observed in the control and FK506 groups versus the PAN group. Cytoplasmic LC3-related fluorescence intensity was stronger in control and FK506 podocytes versus the PAN group. Tacrolimus inhibited puromycin-induced mouse podocyte damage by regulating LC3 expression and enhancing autophagy.

    Citation

    Xiao-Qing Yang, Sheng-You Yu, Li Yu, Lin Ge, Yao Zhang, Zhi-Hong Hao, Guo-Sheng Liu. Effects of tacrolimus on autophagy protein LC3 in puromycin-damaged mouse podocytes. The Journal of international medical research. 2020 Dec;48(12):300060520971422

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33322998

    View Full Text